The Company developing treatments for skin infections and diseases, Botanix Pharmaceuticals (ASX: BOT), has filed a New Drug Application (NDA) submission with the US Food and Drug Administration (FDA) for its Sofpironium Bromide product. The submission will seek FDA approval for the treatment of primary axillary hyperhidrosis. Hyperhidrosis is a rare disorder characterised by excessive
Read More
Energy markets are grappling with tensions between Russia and Saudi Arabia, with a price war emerging post recent OPEC+Russia meeting. ASX energy sector sold off yesterday as a result. Energy valuation summary (prices as of end of day yesterday OPEC+Russia delivers a nasty surprise. Most investors were holding out on the hope that the recent OPEC+Russia
Read More
Sufferers of skin conditions like acne, psoriasis and dermatitis could soon have effective cannabinoid therapeutics thanks to Botanix (ASX:BOT) and their synthetic cannabinoid trials. Presenting at the International Cannabinoid Derived Pharmaceuticals (iCDP) Summit in Boston, the presentation titled Fact or Fiction, highlighted the effectiveness seen in their recently completed clinical trials to treat acne, and
Read More